Researchers with the Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have received $5 million in funding from NCI to establish an HIV-associated Malignancy Research Center focused on lung cancer in East Africa.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
